English
Email Chinese

I-Mab Biopharma and Company Milestones: A China-based global player in innovative biologics


I-Mab Biopharma was established through a merger of Third Venture Biopharma, an innovative antibody start-up, and Tasgen, a joint venture biotech by Tasly Pharmaceuticals, Genexine and C-Bridge Capital. The merged Company now combines novel antibody discovery and regulatory/clinical development expertise from Third Venture Biopharma and Tasgen's unique strength in biologics CMC, QA/QC and pre-clinical development, thus covering the full spectrum of innovative biologics R&D.


The Company successfully completed Series B financing of $150 million led by C-Bridge Capital after the merger in 2017. I-Mab's R&D operations is mainly based in Shanghai with an office in Beijing, specializing in regulatory affairs and clinical operations. The Company has an in-house discovery laboratory and a specialized CMC laboratory. The current pipeline is composed of two portfolios,"In China for Global", focusing on innovative monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune disease, and "In China for China" designed to meet unmet medical need in China. In 2017, I-Mab has been geared towards 3 IND submissions (one Ph 1 and two Ph 2 clinical trials) and subsequent start of two multi-regional clinical trials (Ph 2). As planned, the pipeline will hit a series of critical milestones, including five Ph 1 and Ph 2 clinical trials and five IND submissions (US and/or China) of novel monoclonal or bi-specific antibodies by the end of 2018. In addition to in-house discovery and development efforts, I-Mab is actively seeking partnerships with global biotech or pharmaceutical companies to co-develop innovative clinical assets for China market through I-Mab's unique development expertise. One of the most recent examples is Olamkicept, a Ph 2 ready fusion protein from Ferring (http://www.prnasia.com/story/archive/1877244_ZH77244_1), which is now in a multi-regional clinical trial (Ph 2).


Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210    Tel:86-21-6057 8000     Email:marcom@i-mabbiopharma.com